Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in br… Read more
Novocure Ltd - Asset Resilience Ratio
Novocure Ltd (NVCR) has an Asset Resilience Ratio of 50.79% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Novocure Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Novocure Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $691.38 Million | 50.79% |
| Total Liquid Assets | $691.38 Million | 50.79% |
Asset Resilience Insights
- Very High Liquidity: Novocure Ltd maintains exceptional liquid asset reserves at 50.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Novocure Ltd Industry Peers by Asset Resilience Ratio
Compare Novocure Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 6.64% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
|
Osang Healthcare Co.,Ltd
KQ:036220 |
Medical Devices | 9.34% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
Annual Asset Resilience Ratio for Novocure Ltd (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Novocure Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 64.16% | $796.11 Million | $1.24 Billion | +5.72pp |
| 2023-12-31 | 58.44% | $669.79 Million | $1.15 Billion | -13.23pp |
| 2022-12-31 | 71.67% | $854.10 Million | $1.19 Billion | +7.71pp |
| 2021-12-31 | 63.97% | $728.90 Million | $1.14 Billion | +6.18pp |
| 2020-12-31 | 57.79% | $607.90 Million | $1.05 Billion | +26.76pp |
| 2019-12-31 | 31.03% | $148.77 Million | $479.45 Million | +0.05pp |
| 2018-12-31 | 30.98% | $105.26 Million | $339.79 Million | -8.50pp |
| 2017-12-31 | 39.47% | $104.72 Million | $265.30 Million | -3.02pp |
| 2016-12-31 | 42.49% | $119.85 Million | $282.08 Million | -6.32pp |
| 2015-12-31 | 48.81% | $150.00 Million | $307.34 Million | +10.63pp |
| 2014-12-31 | 38.17% | $45.00 Million | $117.88 Million | +37.55pp |
| 2013-12-31 | 0.62% | $1.18 Million | $188.91 Million | -- |